NEW YORK (Reuters) - Bristol-Myers Squibb Co <BMY.N> set a better-than-expected baseline for profits in 2013 as it provided investors their first glimpse of life after Plavix, the second-largest selling drug in the world. Bristol on Thursday projected 2013 earnings, excluding items, of at least $1.95 per share. That would appear to be a potential decline of ...

Bristol-Myers Squibb and Allergan will jointly attempt to develop a drug to treat chronic pain from tissue damage, the drugmakers said Wednesday. The agreement could eventually be worth $413 million, plus royalty payments. Bristol-Myers will pay Allergan $40 million up front for the rights to the drug ...

Drugmaker Bristol-Myers Squibb Co. said Tuesday its chief executive will retire in May and be succeeded by the current chief operating officer. The move is the fourth official retirement from a senior health company executive position for James M. Cornelius, who had run Bristol-Myers for ...